KDA Group

KDA Group Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of KDA Group (KDA.V) as of Nov 2, 2026 is -0.17. In the previous year, Net Debt to Free Cash Flow Ratio was 3.35 — a change of -105.13% (lower).

Net Debt/FCF

-0.17

YoY

-105.13%

Last updated:

Net Debt to Free Cash Flow Ratio of KDA Group is 2024 -0.17 . Net Debt to Free Cash Flow Ratio of KDA Group was 2023 3.35 . It decreases by -105.13% lower compared to the previous year.

The KDA Group Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2016
-6.70 CAD
Jan 1, 2017
-15.45 CAD
Jan 1, 2018
38.61 CAD
Jan 1, 2019
-3.38 CAD
Jan 1, 2020
-0.35 CAD
Jan 1, 2021
2.03 CAD
Jan 1, 2022
3.35 CAD
Jan 1, 2024
-0.17 CAD
The KDA Group Net Debt/FCF history
YEARNet Debt/FCFYoY
-0.17-105.13%
3.35+64.83%
2.03-680.28%
-0.35-89.64%
-3.38-108.75%
38.61-349.94%
-15.45+130.42%
-6.70+1.47%
-6.61-104.73%
139.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KDA Group Stock analysis

What does KDA Group do? KDA Group, Inc. generates revenue through its Pharmacy Services, Pharmaceutical Solutions, and Pharmaceutical Technology segments. The Pharmacy Services segment provides training, consulting, and replacement services for healthcare professionals. The Pharmaceutical Solutions segment develops and integrates technological platforms for healthcare professionals. The Pharmaceutical Technology segment offers KRX, KRX DENTAL, and ADRX platforms, while ZRx Digital Prescriber is an electronic prescriber software for authorized healthcare providers. Subsidiaries like Alliance Pharma Operations Inc. and Elitis Pharma Inc. support these services. Clients include healthcare professionals who require training, consulting, and technological solutions. The Pharmacy Services segment targets professional resource needs in healthcare, while Pharmaceutical Solutions and Technology segments serve healthcare professionals with integrated platforms and digital tools. Subsidiaries such as Logistik Pharma Inc. and Groupe Technologique KDA Inc. contribute to the company's service delivery. Pharmaceutical Technology platforms like KRX, KRX DENTAL, and ADRX are sold to healthcare professionals seeking digital solutions. ZRx Digital Prescriber is utilized by authorized prescribers for medication and treatment management. The company's subsidiaries operate within the segments to deliver specialized services, ensuring comprehensive solutions for healthcare providers. KDA Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KDA Group stock

Net Debt to Free Cash Flow Ratio of KDA Group is -0.17 in 2024.

Net Debt to Free Cash Flow Ratio of KDA Group changed from 3.35 to -0.17, representing a -105.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio KDA Group since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's KDA Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — KDA Group

All Key Metrics — KDA Group